JANX

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution SAN DIEGO, May 07, 2026--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic," said David Campbell, Ph.D., President and CEO of Janux. "Our ongoing clinical study with JANX011 has been designed to support our emerging autoimmune disease opportunity." BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS: Clinical & Pipeline Progress JANX007 (PSMA-TRACTr) continues to enroll in its Phase 1b trial in metastatic castration-resistant prostate cancer (mCRPC), with ongoing dose optimization and expansion in taxane-naïve patients. An expansion cohort evaluating JANX007 in combination with darolutamide, an androgen receptor pathway inhibitor, is actively enrolling in taxane-naïve mCRPC. JANX014 (PSMA-TRACTr), a double masked tumor-activated T cell engager, has initiated clinical evaluation. Following the completion of the Phase 1a portion of the study and internal review of the data, the Company has discontinued further clinical development of JANX008 (EGFR-TRACTr) and is prioritizing resources toward other pipeline opportunities. JANX011 (CD19-ARM) is actively enrolling in its Phase 1 clinical trial in healthy volunteers. The Company continues to advance additional TRACTr, TRACIr and ARM programs for potential future development. Strategic Collaborations Janux announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen, utilizing Janux’s TRACTr platform. Recently anno...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Amgen and Erasca, as well as updates from Rocket Pharma and Janux Therapeutics that you may have missed. The Food and Drug Administration has officially proposed that Amgen withdraw from market Tavneos, a drug the company acquired in a nearly $4 billion deal in 2022. Amgen disclosed in February that it intended to keep selling Tavneos despite FDA concerns about the drug's clinical results and safety. The FDA stepped up its campaign Monday, publishing a letter to Amgen arguing Tavneos should be pulled because of "new information" showing the drug's approval submissions from former developer ChemoCentryx "contained untrue statements of material fact." According to the agency, "unblinded study personnel manipulated [Tavneos'] results" to make the drug look effective when the original analysis "did not support that conclusion." That initial analysis wasn't disclosed, violating agency regulations, the FDA claimed. Tavneos will remain on the market until Amgen chooses to remove it or is forced to do so by Commissioner Martin Makary. Amgen could also request a public hearing, the FDA said. Shares of Erasca lost nearly half their value despite early clinical data for a drug that, to multiple Wall Street analysts, may be competitive with Revolution Medicines' closely watched pancreatic cancer medicine. Erasca's therapy ERAS-0015 targets "RAS" mutations, as Revolution's does, but was designed to have potentially superior characteristics. Data disclosed Monday showed a 62% unconfirmed response rate in people with second-line, non-small cell lung cancer and a 40% response rate in previously treated pancreatic cancer patients. Erasca said both figures were double-digit percentage points higher than previously reported results from Revolution, and analysts at Evercore ISI and Stifel described the findings as a "home run" and "promising signals of differentiation." Yet Erasca also disclosed that Revolution has accused it of patent infringement and, in a slide presentation, revealed that a treatment recipient who'd experienced a kind of lung tissue inflammation voluntarily withdrew from supportive care and later died. Stifel's Laura Prendergast claimed in a Tuesday note that those factors w...

Elevance Health, Inc. ELV is set to report its first-quarter 2026 results on April 22, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $10.61 per shareon revenues of $48.37 billion. The first-quarter earnings estimate witnessed one downward revision and three upward revisions over the past 60 days. The bottom-line projection indicates a year-over-year decline of 11.4%. Also, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year decrease of 0.8%. Image Source: Zacks Investment Research For 2026, the Zacks Consensus Estimate for Elevance’s revenues is pegged at $194.76 billion, implying a fall of 1.4% year over year. The consensus mark for 2026 EPS is pegged at $25.92, indicating a 14.4% year-over-year decrease. Elevance’s earnings beat the consensus estimate in three of the trailing four quarters and missed once, with the average surprise being 7.9%. This is depicted in the figure below. Elevance Health, Inc. price-eps-surprise | Elevance Health, Inc. Quote Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here. ELV currently has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. The Zacks Consensus Estimate for product revenues indicates 4.9% growth from the year-ago period’s $5.8 billion. The consensus estimate for premiums indicates a 1.8% decrease from the year-ago period. The consensus mark for Commercial Individual membership implies 25.7% fall from a year ago, while our model estimate indicates a 23.7% decline. Also, declining memberships in Medicaid (-8.4%) are likely to have kept first-quarter performance in check. However, the consensus estimate for Commercial Fee-based memberships indicates 0.6% year-over-year growth. Meanwhile, the Zacks Consensus Estimate for Carelon brand’s operating income for the first quarter indicates a 1.7% year-over-year decrease. The consensus estimate for the Health Benefits segment’s operating income for the first quarter indicates a 13.7% year-over-year plunge, making an earnings beat uncertain. The Zacks Consensus Es...

Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution SAN DIEGO, February 26, 2026--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advances. Recent JANX007 clinical results demonstrate clinical activity and a consistent and predictable safety profile in mCRPC and support continued advancement in taxane-naïve patients as well as other expansion cohorts," said David Campbell, Ph.D., President and CEO of Janux. "In early 2026, we announced a collaboration with Bristol Myers Squibb that provides near-term capital and further validates the potential of our platform. We also continue to strengthen our team to support the next phase of clinical and pipeline growth. With additional product candidates entering the clinic in 2026, we believe Janux is well positioned to execute on our clinical strategy and continue to build long-term value for patients and shareholders." BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS: Clinical & Pipeline Progress Janux presented updated interim Phase 1 data for JANX007 (PSMA-TRACTr) in December 2025. As of the October 15, 2025 data cutoff, 109 patients had been treated across Phase 1 cohorts: Durable clinical activity was observed across both once-weekly (QW) and every-two-week (Q2W) cohorts, with median radiographic progression-free survival (rPFS) ranging from 7.9 to 8.9 months. The rPFS in the Q2W cohort compared favorably to the QW expansion group. Data demonstrated high p...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (BMY) is back in focus after two key updates: a new AI lung cancer screening agreement with Microsoft, and positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy. See our latest analysis for Bristol-Myers Squibb. Those AI and cardiology updates come after a busy start to 2026, including oncology focused deals like the new Janux Therapeutics agreement. They follow a 90 day share price return of 25.35% against a weaker 1 year total shareholder return of a 2.41% decline, suggesting recent momentum has picked up after a tougher stretch. If news around AI in healthcare and rare disease pipelines has your attention, it could be a good moment to scan healthcare stocks for other ideas in the sector. With Bristol Myers Squibb trading at $54.94 and carrying a value score of 5 alongside an indicated intrinsic discount of 56.70%, the key question is whether this reflects genuine undervaluation or whether the market is already incorporating expectations for future growth in the price. The most followed narrative puts Bristol Myers Squibb’s fair value at $56.26, just above the recent $54.94 close, and anchors that view in detailed forecasts. Read the complete narrative. Want to understand why a company with expected revenue declines still lands near this fair value mark? The narrative leans heavily on a rebuild in profitability and a future earnings profile that hinges on higher margins and a different earnings mix. Curious which specific earnings and margin paths sit behind that conclusion and how they tie back to today’s price? Result: Fair Value of $56.26 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on Bristol Myers Squibb managing patent cliffs around key drugs and avoiding setbacks in late stage trials, which could weaken the earnings rebuild story. Find out about the key risks to this Bristol-Myers Squibb narrative. If you are not fully on board with this storyline or prefer to test the assumptions yourself, you can build a custom view in minutes, starting with Do it your way. A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 2 important warn...

In early December 2025, Janux Therapeutics reported updated interim Phase 1 data for JANX007 in metastatic castration-resistant prostate cancer, showing anti-tumor activity with partial responses in 30% of evaluable patients and radiographic progression-free survival of 7.9 to 8.9 months. Despite Janux characterizing the results as positive, investors questioned whether JANX007 can compete with established options such as Novartis’s Pluvicto, putting the company’s broader TRACTr platform under closer scrutiny. Next, we’ll examine how concerns about JANX007’s competitive profile in metastatic castration-resistant prostate cancer shape Janux Therapeutics’ investment narrative. We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. To own Janux Therapeutics after the JANX007 update, you have to believe the TRACTr platform can still turn early pharmacology into clinically and commercially relevant drugs, despite a painful reset in expectations. The Phase 1 data showed real anti-tumor activity, but the market’s 40%+ selloff and analyst target cuts suggest JANX007 may no longer be viewed as a clear contender against options like Pluvicto, at least near term. That likely shifts the key catalysts from “how fast can JANX007 scale” to more proof-of-concept questions around dosing, combinations in taxane-naïve and PARP inhibitor–refractory settings, and follow‑on assets such as JANX008 and the CD19-ARM program. At the same time, rising losses, a young management team and reliance on equity markets remain front‑of‑mind risks. However, one emerging risk now goes beyond science and into competitive positioning that investors should not ignore. According our valuation report, there's an indication that Janux Therapeutics' share price might be on the expensive side. Three Simply Wall St Community fair value views span roughly US$48 to US$150 per share, but the recent JANX007 data debate and sharp price reaction show why you may want to compare several such viewpoints. Explore 3 other fair value estimates on Janux Therapeutics - why the stock might be worth over 9x more than the current price! Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Janux Therapeutics research is our analysis...

Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 $989.0 million in cash, cash equivalents, and short-term investments at end of third quarter 2025 SAN DIEGO, November 06, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. "With enrollment ongoing in the JANX007 and JANX008 clinical trials and multiple new drug candidates expected to enter the clinic next year, we remain confident in our ability to advance these programs, supported by a strong balance sheet that enables continued execution," said David Campbell, Ph.D., President and CEO of Janux. RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES: JANX007 continues to enroll in the first-in-human Phase 1 clinical trial in mCRPC (NCT05519449). JANX008 continues to enroll in the first-in-human Phase 1 clinical trial in advanced or metastatic solid tumors (NCT05783622). Additional data from JANX007 and JANX008 will be presented at future Janux events in the fourth quarter of 2025. THIRD QUARTER 2025 FINANCIAL RESULTS: Cash and cash equivalents and short-term investments: As of September 30, 2025, Janux reported cash and cash equivalents and short-term investments of $989.0 million, compared to $1.03 billion at December 31, 2024. Research and development expenses: Research and development expenses for the quarter ended September 30, 2025 were $34.6 million, compared to $18.6 million for the comparable period in 2024. General and administrative expenses: General and administrative expenses for the quarter ended September 30, 2025 were $10.6 million, compared to $17.7 million for the comparable period in 2024. With respect to the quarter ended September 30, 2024, $9.5 million of the general and administrative expense incurred was due to stock-based compensation expense associated with equity modifications. Net loss: For the quarter ended September 30, 2025, Janux reported a net loss of $24.3 million, compared to a net loss of $28.1 million for t...

Net loss: US$57.4m (loss widened by 177% from 1H 2024). US$0.93 loss per share (further deteriorated from US$0.41 loss in 1H 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 3.1% from a week ago. We don't want to rain on the parade too much, but we did also find 4 warning signs for Janux Therapeutics (2 are a bit unpleasant!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 First patient dosed in lead collaboration program triggers $10 million milestone payment from Merck $996.0 million in cash, cash equivalents, and short-term investments at end of second quarter 2025 SAN DIEGO, August 07, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "The recent expansion of our TRACTr, TRACIr, and ARM development programs displays our ability to enact a strategy that attempts to both maximize the benefit and value of our current clinical programs, including JANX007, while continuing to advance other differentiated candidates in oncology and autoimmune disease," said David Campbell, Ph.D., President and CEO of Janux. "We look forward to additional clinical data from JANX007 and JANX008 expected in the second half of 2025." RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES: R&D Day highlighted pipeline progress and novel bispecific platform in autoimmune disease. In July 2025, Janux management presented multiple product candidates identified from its preclinical pipeline to move towards clinical trials. A PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. A TROP2-TRACTr added a first-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. A CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates. JANX007 continues to enroll in the first-in-human Phase 1 clinical trial in mCRPC (NCT05519449). JANX008 continues to enroll in the first-in-human Phase 1...

Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 $1.01 billion in cash, cash equivalents, and short-term investments at end of first quarter 2025 SAN DIEGO, May 08, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "We are proud to advance into the next phase of our clinical journey for JANX007 and begin treating patients in our Phase 1b expansion studies," said David Campbell, Ph.D., President and CEO of Janux. "We also look forward to our first R&D Day where we will unveil previously undisclosed preclinical programs that utilize our expertise and platform technologies to address significant unmet medical needs." RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES: Initiated first Phase 1b expansion study with JANX007 in taxane-naïve mCRPC patients. In December 2024, Janux reported positive interim clinical data from the Phase 1a dose escalation portion of the trial in 16 metastatic castration-resistant prostate cancer (mCRPC) patients with a median of four prior lines of therapy. At that time, the median radiographic progression-free survival (rPFS) reported was 7.4 months for all 16 patients.* As of April 21, 2025, updated results** have been achieved in the same 16 patients supporting the initiation of the Phase 1b expansion studies: Median rPFS of 7.5 months (n=16) Median rPFS of 7.9 months for patients treated at 6mg and 9mg target doses (n=9) 6-month rPFS of 65% (n=16) 6-month rPFS of 78% for patients treated at 6mg and 9mg target doses (n=9) Safety data remained consistent with the December 2024 data disclosure (n=16) *8/16 patients were noted as in-progress in the December 2024 reported results. **rPFS results based upon Kaplan-Meier estimate. Janux selected 0.3/2/6mg and 0.3/2/9mg with dosing administered once weekly or once every two weeks as the two dose...